Insulin glargine - Biologic Drug Details

Summary for insulin glargine

Tradenames:	4
High Confidence Patents:	3
Applicants:	4
BLAs:	7
Suppliers: see list	6
Recent Clinical Trials:	See clinical trials for insulin glargine
Drug Prices:	Drug price information for insulin glargine

Recent Clinical Trials for insulin glargine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Eastern Virginia Medical School	PHASE4
Huadong Hospital	PHASE4
Rutgers, The State University of New Jersey	NA

See all insulin glargine clinical trials

Pharmacology for insulin glargine

Established Pharmacologic Class	Insulin Analog
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin glargine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin glargine Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	5,370,629	2013-10-13	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	5,509,905	2013-10-13	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	5,656,722	2014-09-12	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	BASAGLAR	insulin glargine	Injection	205692	5,618,913	2006-08-29	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for insulin glargine Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	10,004,686	2033-06-12	Patent claims search
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	10,016,338	2036-12-20	Patent claims search
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	10,029,011	2030-11-11	Patent claims search
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	10,092,513	2034-04-01	Patent claims search

International Patents for insulin glargine

Country	Patent Number	Estimated Expiration
Poland	2263721
Canada	2857982
Denmark	0948358
Denmark	2787975

Supplementary Protection Certificates for insulin glargine

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C990042	Netherlands		PRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907
300883	Netherlands		PRODUCT NAME: INSULIN GLARGINE/LIXISENATIDE; REGISTRATION NO/DATE: EU/1/16/1157 20170113
C300019	Netherlands		PRODUCT NAME: INSULINE GLARGINE,DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH GESCHIKT ZOUT; REGISTRATION NO/DATE: EU/1/00/134/001 - 007 20000609
SZ 34/2000	Austria		PRODUCT NAME: LANTUS - INSULIN GLARGIN

Market Dynamics and Financial Trajectory for Insulin Glargine

Last updated: February 25, 2026

What is the Current Market Size and Growth Rate for Insulin Glargine?

Insulin glargine, a long-acting basal insulin, commands a significant portion of the diabetes care market. In 2022, the global insulin market was valued at approximately USD 30 billion. Insulin glargine accounts for roughly 35% of this market, valued at around USD 10.5 billion. The compound annual growth rate (CAGR) from 2022 to 2030 is estimated between 7% and 9%, driven by increasing diabetes prevalence and adoption of basal insulin analogs.

How Do Patent Expirations and Biosimilar Entry Impact Market Dynamics?

Pfizer’s original formulation, LANTUS, was launched in 2000. Its patent expired in 2015 in the U.S., opening opportunities for biosimilar competition. Multiple biosimilars have entered markets across various regions between 2017 and 2020, including:

• Sandoz, Biocon, and Mylan: launched biosimilars in Europe between 2016-2018.
• Amjevita (AbbVie): a biosimilar introduced in the U.S. in 2021.

Despite patent expirations, market share shifts remain limited due to prescriber and payer preferences for established brands, differences in biosimilar pricing strategies, and regulatory pathways.

What Are the Major Global Markets and Regional Trends?

• United States: Largest market, USD 4 billion in 2022. Growth driven by high prevalence and reimbursement policies that favor biosimilar adoption.
• Europe: Approximately USD 3.5 billion, with extensive biosimilar penetration since 2017 due to EU regulatory flexibility.
• Asia-Pacific: Fastest growth, CAGR of around 10%, driven by increasing diabetes prevalence, especially in China and India.

How Do Pricing and Reimbursement Policies Affect Market Trajectory?

Pricing strategies for insulin glargine vary globally:

• In the U.S., list prices for branded options like LANTUS hover around USD 200 per pen, with actual costs to payers lower due to rebates.
• Biosimilars are priced approximately 15-20% lower than branded counterparts.
• Reimbursement policies favor biosimilars where regulatory approvals are secured, but slow uptake persists where physicians prefer original products or where interchangeability status is unclear.

What Are the Competitive Landscape and Key Players?

Major manufacturers include:

• Sanofi: Original innovator, LANTUS (marketed as Toujeo and SAR438710 in biosims).
• Eli Lilly: Basaglar biosimilar, launched in 2016.
• Biocon/ Mylan: Semglee biosimilar, launched in 2018.
• Novo Nordisk: Developing biosimilar insulin glargine, with regulatory filings in progress.

Generic and biosimilar markets are expected to grow, capturing an estimated 25-30% of the insulin glargine market by 2030.

What Are the R&D and Innovation Trends?

Research focuses on improving pharmacokinetics, reducing injection frequency, and integrating insulin delivery with digital health solutions. Companies are exploring ultra-long-acting insulins and biosimilars with enhanced stability and bioavailability.

What Are the Key Regulatory and Pricing Challenges?

Regulatory pathways differ by region; biosimilar approval requires demonstrating similarity in efficacy, safety, and immunogenicity, often through complex clinical trials. Pricing pressures and payer negotiations influence market access, especially for biosimilars. Originator companies respond with strategic patent filings and formulation improvements to extend exclusivity.

How Do External Factors Influence Market and Financial Outcomes?

• Increasing global diabetes prevalence projected to reach 700 million by 2045 (IDF, 2021).
• Healthcare policies emphasizing cost containment favor biosimilar adoption.
• Technological innovations such as connected insulin pens and real-time monitoring influence patient adherence and prescribing patterns.

Projected Financial Trajectory

The insulin glargine market is expected to grow from USD 10.5 billion in 2022 to approximately USD 17-20 billion by 2030. Growth will be driven primarily by genericization, regional market expansion, and innovation in delivery systems.

• Biosimilar revenue share: Estimated to reach 30% across the global market by 2030.
• Pricing trends: Biosimilars likely to continue undercutting branded products by 15-20%, pressuring original manufacturers.
• Market players: Revenue diversification with biosimilar proliferation may erode profit margins of established brands but also open opportunities for new entrants.

Key Takeaways

• The insulin glargine market is large and growing, with a CAGR near 8%.
• Patent expirations have initiated biosimilar entry, but market share shifts are incremental.
• Regional disparities exist, with Asia-Pacific showing rapid growth.
• Pricing and reimbursement policies significantly influence biosimilar adoption.
• Innovations and regulatory pathways shape competitive dynamics and financial outcomes.

FAQs

1. Will biosimilars significantly impact insulin glargine revenues by 2030?
Yes. Biosimilars are projected to take up approximately 30% of the market, reducing revenues for original products but expanding overall market size.

2. How do patent expirations influence market entry?
Patent expirations open the market to biosimilar manufacturers, increasing competition and driving down prices, though actual market penetration depends on regional policies and physician acceptance.

3. Are insulins with longer durations of action gaining market share?
Yes. Ultra-long-acting insulins are being developed, offering potential advantages in dosing convenience, though insulins glyce-based market dominance remains robust.

4. What regional factors can accelerate biosimilar adoption?
Effective reimbursement policies, regulatory pathways favoring biosimilars, and cost sensitivity in healthcare systems promote adoption, especially in Europe and Asia.

5. How might technological advances influence future market dynamics?
Integration with digital health tools and innovative delivery devices can improve patient adherence, potentially expanding the market and influencing financial trajectories.

---

References

[1] International Diabetes Federation. (2021). IDF Diabetes Atlas, 10th edition.